Panel Discussion: Rare, Diabetic & Hypertensive Kidney Disease: What do Payers & Regulators Need to See?

Time: 3:00 pm
day: Track 2 - Day 1 PM


• Beyond hard endpoints: what is an approvable and achievable endpoint in diabetic and rare kidney
• Harmonizing global regulations and patient metrics
• Considering future principles of reimbursement and benchmarking clinical benefit in the context of new approved therapies